74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Aurinia Pharmaceuticals Inc
Closed
SectorHealthcare
8.04 -1.71
Overview
Share price change
24h
Min
7.87
Max
8.19
Income | -13M 1.4M |
|---|---|
Sales | -7.9M 60M |
P/E Sector Avg | 201 63.778 |
EPS | 0.01 |
Profit margin | 2.387 |
Employees | 130 |
EBITDA | -14M 7.2M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +19.05% upside |
Next Earnings | 1 May 2025 |
|---|
Market Cap | -13M 1.1B |
|---|---|
Previous open | 9.75 |
Previous close | 8.04 |
News Sentiment
By Acuity
50%
50%
180 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Aurinia Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Aurinia Pharmaceuticals Inc Forecast
Price Target
By TipRanks
19.05% upside
12 Months Forecast
Average 9.75 USD 19.05%
High 11 USD
Low 8 USD
Based on 4 Wall Street analysts offering 12 month price targets forAurinia Pharmaceuticals Inc - Dist in the last 3 months.
Sentiment
By Acuity
180 / 386 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
